Apellis Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Apellis Pharmaceuticals
APLS Stock  USD 34.14  1.51  4.63%   
Apellis Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Apellis Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Apellis Pharmaceuticals financial statements helps investors assess Apellis Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Apellis Pharmaceuticals' valuation are summarized below:
Gross Profit
69.8 M
Profit Margin
(0.35)
Market Capitalization
4.2 B
Enterprise Value Revenue
5.778
Revenue
715.2 M
There are over one hundred nineteen available fundamental signals for Apellis Pharmaceuticals, which can be analyzed over time and compared to other ratios. All traders should validate Apellis Pharmaceuticals' prevailing fundamentals against the performance from 2010 to 2024 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 1.8 B in 2024. Enterprise Value is likely to gain to about 1.6 B in 2024

Apellis Pharmaceuticals Total Revenue

416.42 Million

Check Apellis Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Apellis Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.6 M, Interest Expense of 31.1 M or Selling General Administrative of 525.9 M, as well as many indicators such as Price To Sales Ratio of 33.56, Dividend Yield of 0.0 or PTB Ratio of 19.3. Apellis financial statements analysis is a perfect complement when working with Apellis Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Apellis Pharmaceuticals Correlation against competitors.
For more information on how to buy Apellis Stock please use our How to Invest in Apellis Pharmaceuticals guide.

Apellis Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets425.1 M788.7 M312.8 M
Slightly volatile
Other Current Liabilities213.8 M203.6 M55.7 M
Slightly volatile
Total Current Liabilities260 M247.6 M69 M
Slightly volatile
Total Stockholder Equity118.8 M194.5 M88 M
Slightly volatile
Property Plant And Equipment Net17.7 M21.1 M12.9 M
Slightly volatile
Accounts Payable39.4 M37.5 M11.3 M
Slightly volatile
Cash289.2 M351.2 M213 M
Slightly volatile
Non Current Assets Total18.2 M22.4 M13.3 M
Slightly volatile
Cash And Short Term Investments326.5 M352.3 M240.4 M
Slightly volatile
Net Receivables216.8 M206.4 M33.2 M
Slightly volatile
Common Stock Total Equity9.7 K9.2 K4.4 K
Slightly volatile
Common Stock Shares Outstanding124.6 M118.7 M51.1 M
Slightly volatile
Liabilities And Stockholders Equity425.1 M788.7 M312.8 M
Slightly volatile
Inventory153.7 M146.4 M26.9 M
Slightly volatile
Other Current Assets64.3 M61.2 M21.3 M
Slightly volatile
Other Stockholder Equity3.2 B3 B874 M
Slightly volatile
Total Liabilities306.3 M594.2 M224.8 M
Slightly volatile
Property Plant And Equipment Gross17.7 M21.1 M12.9 M
Slightly volatile
Total Current Assets406.9 M766.3 M299.5 M
Slightly volatile
Common Stock6.2 K12 K4.7 K
Slightly volatile
Non Currrent Assets Other1.2 M1.3 M4.7 M
Slightly volatile
Other Assets19.1 M18.2 M7 M
Slightly volatile
Property Plant Equipment16.9 M28.6 M9.4 M
Slightly volatile
Capital Surpluse743.6 M708.2 M323.7 M
Slightly volatile
Preferred Stock Total Equity93.1 M105.9 M87.1 M
Slightly volatile
Short and Long Term Debt Total164.8 M110.9 M105.5 M
Slightly volatile
Other Liabilities192.4 M363 M107.1 M
Slightly volatile
Long Term Debt145.8 M93 M83.9 M
Slightly volatile
Long Term Debt Total172.1 M164 M76.2 M
Slightly volatile
Net Invested Capital320.8 M287.6 M239.3 M
Slightly volatile
Short and Long Term Debt1.4 M1.5 M14.8 M
Slightly volatile
Net Working Capital506 M518.7 M330.3 M
Slightly volatile
Short Term Debt5.8 M6.4 M16.1 M
Slightly volatile
Capital Stock9.7 K12 K7.2 K
Slightly volatile
Capital Lease Obligations20.3 M17.9 M16.2 M
Slightly volatile
Current Deferred Revenue86.1 M92.9 M107.8 M
Slightly volatile
Short Term Investments1.1 M1.1 M233.3 M
Slightly volatile
Non Current Liabilities Other240.8 M242.1 M329.4 M
Slightly volatile

Apellis Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.6 M1.7 M4.6 M
Very volatile
Selling General Administrative525.9 M500.8 M116 M
Slightly volatile
Other Operating Expenses959.4 M913.7 M276.8 M
Slightly volatile
Research Development187.6 M354.4 M138.1 M
Slightly volatile
Total Operating Expenses898 M855.2 M266.4 M
Slightly volatile
Non Recurring21.2 M23.8 M26 M
Slightly volatile
Interest Income22 M20.9 M4.4 M
Slightly volatile
Reconciled Depreciation1 M1.7 M461.1 K
Slightly volatile
Tax Provision1.4 M2.1 M1.7 M
Slightly volatile
Selling And Marketing Expenses1.4 M1.5 M1.7 M
Slightly volatile

Apellis Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation111.2 M105.9 M30.8 M
Slightly volatile
Begin Period Cash Flow580.7 M553.1 M208.7 M
Slightly volatile
Depreciation1.8 M1.7 M525.6 K
Slightly volatile
Other Non Cash Items15.4 M26.4 M10.4 M
Slightly volatile
Total Cash From Financing Activities264.4 M394.5 M195.4 M
Slightly volatile
End Period Cash Flow289.7 M352.3 M213.4 M
Slightly volatile
Net Borrowings389.9 M371.3 M153.9 M
Slightly volatile
Change To Netincome183.7 M174.9 M67.7 M
Slightly volatile
Issuance Of Capital Stock324 M384.4 M209.4 M
Slightly volatile
Dividends Paid258.3 M290.6 M316.4 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio33.5617.912824.8582
Slightly volatile
PTB Ratio19.336.520830.2007
Slightly volatile
Days Sales Outstanding20019058.8505
Slightly volatile
Book Value Per Share1.951.63911.9661
Pretty Stable
Average Payables3.4 M6.3 M4.3 M
Slightly volatile
Stock Based Compensation To Revenue0.250.26710.3185
Slightly volatile
Capex To Depreciation0.430.45364.1072
Pretty Stable
PB Ratio19.336.520830.2007
Slightly volatile
EV To Sales30.8317.30723.2669
Slightly volatile
Inventory Turnover0.210.39980.3005
Slightly volatile
Days Of Inventory On Hand1.5 K913609
Slightly volatile
Payables Turnover1.481.559610.9495
Slightly volatile
Sales General And Administrative To Revenue1.631.26281.0227
Slightly volatile
Average Inventory7.7 M7.3 M2.2 M
Slightly volatile
Research And Ddevelopement To Revenue0.850.89361.7575
Slightly volatile
Capex To Revenue0.00190.00190.0186
Slightly volatile
Cash Per Share3.942.96853.9249
Slightly volatile
Days Payables Outstanding460234312
Slightly volatile
Income Quality0.651.12510.8122
Pretty Stable
Current Ratio2.943.09518.8209
Slightly volatile
Tangible Book Value Per Share1.951.63911.9661
Pretty Stable
Receivables Turnover1.831.92118.6923
Slightly volatile
Graham Number10.0212.816810.0712
Slightly volatile
Shareholders Equity Per Share1.951.63911.9661
Pretty Stable
Debt To Equity0.450.47830.6671
Slightly volatile
Capex Per Share0.00620.00650.0169
Slightly volatile
Revenue Per Share2.243.34172.9175
Slightly volatile
Interest Debt Per Share0.981.03321.9334
Very volatile
Debt To Assets0.230.1180.1815
Slightly volatile
Operating Cycle1.6 K1.1 K658
Slightly volatile
Price Book Value Ratio19.336.520830.2007
Slightly volatile
Days Of Payables Outstanding460234312
Slightly volatile
Ebt Per Ebit0.881.01811.0646
Slightly volatile
Company Equity Multiplier2.624.05472.8045
Slightly volatile
Long Term Debt To Capitalization0.330.32350.2852
Slightly volatile
Total Debt To Capitalization0.330.32350.2859
Slightly volatile
Debt Equity Ratio0.450.47830.6671
Slightly volatile
Quick Ratio2.382.5048.5584
Pretty Stable
Net Income Per E B T0.81.0040.9798
Very volatile
Cash Ratio1.351.41847.7751
Slightly volatile
Days Of Inventory Outstanding1.5 K913609
Slightly volatile
Days Of Sales Outstanding20019058.8505
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.00131.0133
Slightly volatile
Price To Book Ratio19.336.520830.2007
Slightly volatile
Fixed Asset Turnover19.7418.804710.4374
Pretty Stable
Debt Ratio0.230.1180.1815
Slightly volatile
Price Sales Ratio33.5617.912824.8582
Slightly volatile
Asset Turnover0.530.50280.2719
Pretty Stable
Gross Profit Margin0.990.85250.906
Slightly volatile
Price Fair Value19.336.520830.2007
Slightly volatile

Apellis Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.8 B1.7 B1 B
Slightly volatile
Enterprise Value1.6 B1.5 B902.9 M
Slightly volatile

Apellis Fundamental Market Drivers

Cash And Short Term Investments352.3 M

Apellis Upcoming Events

20th of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Apellis Pharmaceuticals Financial Statements

Apellis Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Apellis Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Apellis Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Apellis Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue92.9 M86.1 M
Total Revenue396.6 M416.4 M
Cost Of Revenue58.5 M61.7 M
Stock Based Compensation To Revenue 0.27  0.25 
Sales General And Administrative To Revenue 1.26  1.63 
Research And Ddevelopement To Revenue 0.89  0.85 
Revenue Per Share 3.34  2.24 
Ebit Per Revenue(1.30)(1.37)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Apellis Stock Analysis

When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY